drugset / Trial / NCT05359224
Low Dose Prasugrel vs Clopidogrel for Stenting or Flow Diverter for Unruptured Aneurysm
Phase 4
Unknown
406 enrolled
Yonsei University
Bucheon St. Mary's Hospital · collabEwha Womans University Seoul Hospital · collabGangnam Severance Hospital · collabInternational St. Mary's Hospital · collabSeverance Hospital · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
Low clopidogrel response has been reported in about 5-44% of the total population, which is associated with an increase in thromboembolism. Recently prasugrel drug widely accepted as a good option for these patients. The purpose of this study is to compare the safety and usefulness of prasugrel versus clopidogrel in patients who are scheduled to undergo stent or diverter treatment for non-ruptured cerebral aneurysms.
Timeline
- Start
- 2022-06-13
- Primary completion
- 2025-07
- Completion
- 2025-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Clopidogrel | Small molecule | 75 mg | — |
| Comparator | Prasugrel | Small molecule | 5 mg | — |